entertainment -WSS

entertainment

author：focus 2025-09-07 17:16:54 - browse：8

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Pediatric cancer treatments threatened by a new FDA policy

WSS

Tuskegee Airman Raymond Cassagnol dies at 102

What to do when lifesaving products contribute to climate change

UnitedHealth wins $3.3 billion takeover of Amedisys

Supreme Court strikes down Biden student loan forgiveness program

What to do when lifesaving products contribute to climate change

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

New air purifier tech could be key to improving indoor air quality

Ukrainian soldiers say they owe lives to US

Heart attack and stroke risk calculators need revising

ADA: All diabetes patients should be screened for liver condition

How one medical school became remarkably diverse

Flagship Pioneering launches a new biotech in two countries

Alkermes shareholders re

U.K. Biobank has 500,000 peoples' genome sequences available

Medical records are filled with copy

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

explore

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

How to pay for weight loss drugs and save Medicare

Will the market for weight loss drugs really reach $100 billion?

Tuskegee Airman Raymond Cassagnol dies at 102

U.K. Biobank has 500,000 peoples' genome sequences available

The simple reason for the increase in autism diagnosis

leisure time

explore

explore

knowledge